Breaking News, Collaborations & Alliances

Wave & Takeda Form Strategic Collaboration

To discover, develop and commercialize nucleic acid therapies for central nervous system disorders

Wave Life Sciences has entered a global strategic collaboration with Takeda to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system (CNS).  Under the collaboration, Wave will provide Takeda the option to co-develop and co-commercialize programs in Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and spinocerebellar ataxia type 3 (SCA3). In addition, Takeda will have the right to license multiple...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters